232 related articles for article (PubMed ID: 25080279)
1. Injectable testosterone undecanoate for the treatment of hypogonadism.
Corona G; Maseroli E; Maggi M
Expert Opin Pharmacother; 2014 Sep; 15(13):1903-26. PubMed ID: 25080279
[TBL] [Abstract][Full Text] [Related]
2. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
4. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
[TBL] [Abstract][Full Text] [Related]
5. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
6. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
[TBL] [Abstract][Full Text] [Related]
8. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
[TBL] [Abstract][Full Text] [Related]
9. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
10. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome.
Park MG; Yeo JK; Cho DY; Kim JW; Kim JW; Oh MM; Kim JJ; Moon du G
J Sex Med; 2015 Apr; 12(4):966-74. PubMed ID: 25648342
[TBL] [Abstract][Full Text] [Related]
13. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
Haider KS; Haider A; Doros G; Traish A
J Urol; 2018 Jan; 199(1):257-265. PubMed ID: 28728990
[TBL] [Abstract][Full Text] [Related]
17. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
[TBL] [Abstract][Full Text] [Related]
18. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
Yassin AA; Nettleship JE; Salman M; Almehmadi Y
Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
20. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
Permpongkosol S; Tantirangsee N; Ratana-olarn K
J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
